HUM stock sentiment todayHumana Inc.
Sentiment verdict
Gossip first, financials second — COLD at 75% confidence.
Last updated · cached analysis, refreshes periodically
HUM
Humana Inc.Humana is facing a 'perfect storm' of Medicare Advantage margin compression, rising medical loss ratios, and recent Star Rating downgrades that threaten future subsidies.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for HUM. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the 'Medicare Advantage crisis.' Investors are reeling from a massive drop in 4-star rated plans for 2025 and ongoing concerns about rising utilization costs (outpatient care). While M&A rumors involving Cigna occasionally resurface to provide a floor, the prevailing chatter is focused on regulatory headwinds and earnings misses.
- ·CMS Star Rating declines (from 94% to 25% of members in 4+ star plans)
- ·Higher-than-expected medical utilization post-COVID
- ·Regulatory scrutiny on Medicare Advantage coding and reimbursements
- ·Persistent M&A speculation with CI
Financial
Humana’s fundamentals are under significant pressure as the Medical Benefit Ratio (MBR) has spiked toward 90%. While the balance sheet remains functional, the earnings trajectory for 2024-2025 has been severely reset downward due to higher claim costs and lower government bonuses.
- ·Forward P/E ~18x (elevated relative to historical growth profile)
- ·Medical Benefit Ratio (MBR) near 90% (up from historical mid-80s)
- ·Debt-to-Equity ~0.65
- ·Significant EPS guidance cuts in recent quarters
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Revenue loss from decreased quality bonus payments (Star Ratings)
- ·Continued trend of high medical cost utilization by seniors
- ·Regulatory caps on Medicare Advantage reimbursement rates
- ·Integration risks if a mega-merger is pursued
Peer temperature
How direct competitors stack up against HUM right now.
- HOTUNHUnitedHealth Group
HOTTER — offers superior diversification via Optum's services and tech, insulating it from the MA-specific headwinds crushing Humana.
See full analysis → - NEUTRALELVElevance Health
WARMER — better protected by a larger commercial insurance footprint and less reliance on the volatile Medicare Advantage segment.
See full analysis → - COLDCVSCVS Health (Aetna)
COLDER — suffering from similar MA headwinds plus massive retail pharmacy drag and higher debt load from the Oak Street Health acquisition.
See full analysis →
- HUM+10.4%
- UNH-3.8%
- ELV+4.2%
- CVS-2.4%
Analyst price target
Consensus average of 22 analysts · median 425.00
Source: StockAnalysis.com · updated 2026-09-08
AI-generated analysis for informational purposes only. Not financial advice.